Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
Identifieur interne : 003959 ( PubMed/Curation ); précédent : 003958; suivant : 003960Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
Auteurs : Diego Garcia-Borreguero [Espagne] ; Ana B. Caminero ; Yolanda De La Llave ; Oscar Larrosa ; Soledad Barrio ; Juan J. Granizo ; Juan A. ParejaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Aged, Dopamine Agonists (pharmacology), Dopamine Agonists (therapeutic use), Electromyography (drug effects), Female, Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Movement Disorders (diagnosis), Muscle Tonus (drug effects), Parkinson Disease (drug therapy), Severity of Illness Index, Sleep, REM (drug effects).
- MESH :
- chemical , pharmacology : Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- diagnosis : Movement Disorders.
- drug effects : Electromyography, Muscle Tonus, Sleep, REM.
- drug therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Severity of Illness Index.
Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) is frequently associated with Parkinson's disease (PD) and may anticipate its diagnosis by several years. We assessed the presence of motor dyscontrol during REM sleep in treatment-naïve PD patients and investigated the putative effect of levodopa (L-dopa) treatment on motor activity. Overnight sleep studies were performed on 15 previously untreated PD patients and 14 controls at baseline, again after a 3- to 9-month treatment period with a low dose of L-dopa, and 2 to 5 days after treatment discontinuation (in 8 patients). No differences in sleep parameters were observed across groups or treatment conditions. None of the patients met criteria for RBD at baseline, whereas 5 patients were symptomatic at the time of the second sleep study. A quantitative analysis of electromyographic (EMG) activity during REM sleep showed a lower phasic twitching activity in untreated PD than in controls. However, an increase in both phasic twitching and tonic activity was found after treatment with L-dopa. Discontinuation of treatment resulted in a return to pretreatment values of phasic but not of tonic EMG activity. Thus, the increase in phasic activity seems to depend on the effects of L-dopa, whereas the increase in tonic EMG activity during REM sleep might be caused by other factors such as the progression of disease. Potential implications for the understanding of the relationship between RBD and PD are discussed.
DOI: 10.1002/mds.10233
PubMed: 12360542
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003959
Links to Exploration step
pubmed:12360542Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.</title><author><name sortKey="Garcia Borreguero, Diego" sort="Garcia Borreguero, Diego" uniqKey="Garcia Borreguero D" first="Diego" last="Garcia-Borreguero">Diego Garcia-Borreguero</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Fundación Jiménez Diaz, Madrid, Spain. dgarciaborreguero@fjd.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Fundación Jiménez Diaz, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Caminero, Ana B" sort="Caminero, Ana B" uniqKey="Caminero A" first="Ana B" last="Caminero">Ana B. Caminero</name></author><author><name sortKey="De La Llave, Yolanda" sort="De La Llave, Yolanda" uniqKey="De La Llave Y" first="Yolanda" last="De La Llave">Yolanda De La Llave</name></author><author><name sortKey="Larrosa, Oscar" sort="Larrosa, Oscar" uniqKey="Larrosa O" first="Oscar" last="Larrosa">Oscar Larrosa</name></author><author><name sortKey="Barrio, Soledad" sort="Barrio, Soledad" uniqKey="Barrio S" first="Soledad" last="Barrio">Soledad Barrio</name></author><author><name sortKey="Granizo, Juan J" sort="Granizo, Juan J" uniqKey="Granizo J" first="Juan J" last="Granizo">Juan J. Granizo</name></author><author><name sortKey="Pareja, Juan A" sort="Pareja, Juan A" uniqKey="Pareja J" first="Juan A" last="Pareja">Juan A. Pareja</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12360542</idno><idno type="pmid">12360542</idno><idno type="doi">10.1002/mds.10233</idno><idno type="wicri:Area/PubMed/Corpus">003959</idno><idno type="wicri:Area/PubMed/Curation">003959</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.</title><author><name sortKey="Garcia Borreguero, Diego" sort="Garcia Borreguero, Diego" uniqKey="Garcia Borreguero D" first="Diego" last="Garcia-Borreguero">Diego Garcia-Borreguero</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Fundación Jiménez Diaz, Madrid, Spain. dgarciaborreguero@fjd.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Fundación Jiménez Diaz, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Caminero, Ana B" sort="Caminero, Ana B" uniqKey="Caminero A" first="Ana B" last="Caminero">Ana B. Caminero</name></author><author><name sortKey="De La Llave, Yolanda" sort="De La Llave, Yolanda" uniqKey="De La Llave Y" first="Yolanda" last="De La Llave">Yolanda De La Llave</name></author><author><name sortKey="Larrosa, Oscar" sort="Larrosa, Oscar" uniqKey="Larrosa O" first="Oscar" last="Larrosa">Oscar Larrosa</name></author><author><name sortKey="Barrio, Soledad" sort="Barrio, Soledad" uniqKey="Barrio S" first="Soledad" last="Barrio">Soledad Barrio</name></author><author><name sortKey="Granizo, Juan J" sort="Granizo, Juan J" uniqKey="Granizo J" first="Juan J" last="Granizo">Juan J. Granizo</name></author><author><name sortKey="Pareja, Juan A" sort="Pareja, Juan A" uniqKey="Pareja J" first="Juan A" last="Pareja">Juan A. Pareja</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Electromyography (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Movement Disorders (diagnosis)</term><term>Muscle Tonus (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Sleep, REM (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electromyography</term><term>Muscle Tonus</term><term>Sleep, REM</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rapid eye movement (REM) sleep behavior disorder (RBD) is frequently associated with Parkinson's disease (PD) and may anticipate its diagnosis by several years. We assessed the presence of motor dyscontrol during REM sleep in treatment-naïve PD patients and investigated the putative effect of levodopa (L-dopa) treatment on motor activity. Overnight sleep studies were performed on 15 previously untreated PD patients and 14 controls at baseline, again after a 3- to 9-month treatment period with a low dose of L-dopa, and 2 to 5 days after treatment discontinuation (in 8 patients). No differences in sleep parameters were observed across groups or treatment conditions. None of the patients met criteria for RBD at baseline, whereas 5 patients were symptomatic at the time of the second sleep study. A quantitative analysis of electromyographic (EMG) activity during REM sleep showed a lower phasic twitching activity in untreated PD than in controls. However, an increase in both phasic twitching and tonic activity was found after treatment with L-dopa. Discontinuation of treatment resulted in a return to pretreatment values of phasic but not of tonic EMG activity. Thus, the increase in phasic activity seems to depend on the effects of L-dopa, whereas the increase in tonic EMG activity during REM sleep might be caused by other factors such as the progression of disease. Potential implications for the understanding of the relationship between RBD and PD are discussed.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12360542</PMID><DateCreated><Year>2002</Year><Month>10</Month><Day>02</Day></DateCreated><DateCompleted><Year>2003</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.</ArticleTitle><Pagination><MedlinePgn>934-41</MedlinePgn></Pagination><Abstract><AbstractText>Rapid eye movement (REM) sleep behavior disorder (RBD) is frequently associated with Parkinson's disease (PD) and may anticipate its diagnosis by several years. We assessed the presence of motor dyscontrol during REM sleep in treatment-naïve PD patients and investigated the putative effect of levodopa (L-dopa) treatment on motor activity. Overnight sleep studies were performed on 15 previously untreated PD patients and 14 controls at baseline, again after a 3- to 9-month treatment period with a low dose of L-dopa, and 2 to 5 days after treatment discontinuation (in 8 patients). No differences in sleep parameters were observed across groups or treatment conditions. None of the patients met criteria for RBD at baseline, whereas 5 patients were symptomatic at the time of the second sleep study. A quantitative analysis of electromyographic (EMG) activity during REM sleep showed a lower phasic twitching activity in untreated PD than in controls. However, an increase in both phasic twitching and tonic activity was found after treatment with L-dopa. Discontinuation of treatment resulted in a return to pretreatment values of phasic but not of tonic EMG activity. Thus, the increase in phasic activity seems to depend on the effects of L-dopa, whereas the increase in tonic EMG activity during REM sleep might be caused by other factors such as the progression of disease. Potential implications for the understanding of the relationship between RBD and PD are discussed.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Borreguero</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fundación Jiménez Diaz, Madrid, Spain. dgarciaborreguero@fjd.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caminero</LastName><ForeName>Ana B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>De La Llave</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Larrosa</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Barrio</LastName><ForeName>Soledad</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Granizo</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Pareja</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009129">Muscle Tonus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012895">Sleep, REM</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>9</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12360542</ArticleId><ArticleId IdType="doi">10.1002/mds.10233</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003959 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003959 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:12360542
|texte= Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:12360542" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |